Referred to the House Committee on Energy and Commerce.
This bill directs the National Institutes of Health (NIH) to reinstate and treat as obligated any NIH grant or award that was terminated or suspended during the period beginning January 20, 2025 and ending on the date of enactment, unless the NIH Director finds financial mismanagement, research fraud, or malfeasance. It requires NIH to disburse payment requests from recipients of such covered grants within 30 calendar days of submission.
Progressives emphasize protecting scientific independence and quickly restoring funds; conservatives emphasize preserving agency discretion and safeguards for safety/national-security/legal concerns.
Relative to its intended legislative type, this bill clearly sets a narrowly scoped substantive policy requirement directing NIH to reinstate and disburse funds for grants suspended or terminated in a defined window, with specific timing requirements and definitions.
This bill directs the National Institutes of Health (NIH) to reinstate and treat as obligated any NIH grant or award that was terminated or suspended during the period beginning January 20, 2025 and ending on the date of enactment, unless the NIH Director finds financial mismanagement, research fraud, or malfeasance.
It requires NIH to disburse payment requests from recipients of such covered grants within 30 calendar days of submission.
Any covered grant or award reinstated or disbursed under the bill receives a one-year extension of its budget period.
On content alone the bill is narrow and operationally simple, which helps passage prospects; however, it directly intervenes in agency grant decisions taken during a recent time window and is framed in a partisan/person-specific way. Those factors increase controversy and reduce the chance of broad bipartisan support, particularly in the Senate where supermajority thresholds or broader consensus are commonly required for contentious measures. The absence of fiscal detail or built-in compromise increases uncertainty and opposition risk.
Relative to its intended legislative type, this bill clearly sets a narrowly scoped substantive policy requirement directing NIH to reinstate and disburse funds for grants suspended or terminated in a defined window, with specific timing requirements and definitions. However, it lacks critical fiscal, procedural, and oversight detail that would normally accompany a statutory obligation to obligate and disburse federal funds.
Progressives emphasize protecting scientific independence and quickly restoring funds; conservatives emphasize preserving agency discretion and safeguards for safety/national-security/legal concerns.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize protecting scientific independence and quickly restoring funds; conservatives emphasize preserving agency discretion and safeguards for safety/national-security/legal concerns.
A mainstream progressive would likely view this bill as a corrective measure to protect scientific independence and researchers from politically motivated or unjustified suspensions of federally funded research.
They would emphasize that the narrow exceptions (financial mismanagement, research fraud, malfeasance) still allow accountability while preventing policy- or ideology-driven cuts.
The 30-day payment requirement and one-year budget extension would be seen as practical steps to stabilize research programs and protect employees and trainees.
A pragmatic moderate would see this bill as a targeted attempt to restore research continuity for grantees affected by suspensions or terminations, while recognizing the need for NIH to retain the ability to act when misconduct or mismanagement occurs.
They would welcome measures that prevent arbitrary disruptions but would be concerned about potential unintended constraints on legitimate agency oversight and implementation logistics.
They would focus on implementation details, transparency, and whether the bill creates financial or legal conflicts with existing appropriations or authority.
A mainstream conservative would likely be skeptical of a law that constrains agency discretion to suspend or terminate grants and that mandates reinstatement and rapid disbursement.
They may view the bill as interfering with NIH’s management and oversight functions and potentially forcing payment for projects the administration paused for policy, safety, or legal reasons.
They would also be concerned about precedent of Congress micromanaging agency grants administration and possible fiscal or legal consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is narrow and operationally simple, which helps passage prospects; however, it directly intervenes in agency grant decisions taken during a recent time window and is framed in a partisan/person-specific way. Those factors increase controversy and reduce the chance of broad bipartisan support, particularly in the Senate where supermajority thresholds or broader consensus are commonly required for contentious measures. The absence of fiscal detail or built-in compromise increases uncertainty and opposition risk.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize protecting scientific independence and quickly restoring funds; conservatives emphasize preserving agency discretion…
On content alone the bill is narrow and operationally simple, which helps passage prospects; however, it directly intervenes in agency gran…
Relative to its intended legislative type, this bill clearly sets a narrowly scoped substantive policy requirement directing NIH to reinstate and disburse funds for grants suspended or terminated in a defined window, wi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.